6/28/23, 1:15 AM DAPA-CKD Pathway Feedback Search Clinical Topics Home Studies DAPA CKD DAPA CKD Disease Chronic kidney disease Trial question What is the role of dapagliflozin in patients with CKD? Study design Multi-center Double blinded RCT Population Characteristics of study participants 33.0% female N = 4304 67.0% male 4304 patients (1425 female, 2879 male) Inclusion criteria: adult patients with CKD Key exclusion criteria: documented diagnosis of T1DM; polycystic kidney disease; lupus nephritis, or ANCA-associated vasculitis; receipt of immunotherapy for kidney disease within 6 months Interventions N=2152 dapagliflozin (10 mg once daily) N=2152 placebo (matching placebo once daily) Primary outcome Composite outcome of sustained decline in estimated glomerular filtration rate of 50%, end-stage kidney disease, or death from renal or cardiovascular causes https://web.pathway.md/studies/recaZd1qTKPQkTkMy 1/2 6/28/23, 1:15 AM DAPA-CKD Pathway 14.5 % 14.5 10.9 % 9.2 7.3 % Significant decrease 3.6 % NNT = 19 0.0 % Dapagliflozin Placebo Significant decrease in composite outcome of sustained decline in the eGFR of 50%, end-stage kidney disease, or death from renal or cardiovascular causes (9.2% vs. 14.5%; HR 0.61, 95% CI 0.51 to 0.72) Secondary outcomes Significant decrease in composite outcome of sustained decline in the eGFR of 50%, end-stage kidney disease, or death from renal causes (6.6% vs. 11.3%; HR 0.56, 95% CI 0.45 to 0.68) Significant decrease in composite outcome of death from cardiovascular causes or hospitalization for HF (4.6% vs. 6.4%; HR 0.71, 95% CI 0.55 to 0.92) Significant decrease in death from any cause (4.7% vs. 6.8%; HR 0.69, 95% CI 0.53 to 0.88) Safety outcomes No significant differences in renal-related adverse event, amputation, fracture. Significant difference in serious adverse event (29.5% vs. 33.9%). Conclusion In adult patients with CKD, dapagliflozin was superior to placebo with respect to the composite outcome of sustained decline in the eGFR of 50%, end-stage kidney disease, or death from renal or cardiovascular causes. Reference Hiddo J L Heerspink, Bergur V Stef nsson, Ricardo Correa-Rotter et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. Open reference URL https://web.pathway.md/studies/recaZd1qTKPQkTkMy 2/2